243 related articles for article (PubMed ID: 32528119)
1. Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner.
Shen W; Zhang X; Du R; Gao W; Wang J; Bao Y; Yang W; Luo N; Li J
Br J Cancer; 2020 Sep; 123(5):730-741. PubMed ID: 32528119
[TBL] [Abstract][Full Text] [Related]
2. Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner.
Zhang X; Du R; Luo N; Xiang R; Shen W
Stem Cell Res Ther; 2020 Aug; 11(1):370. PubMed ID: 32854760
[TBL] [Abstract][Full Text] [Related]
3. ICAM3 mediates inflammatory signaling to promote cancer cell stemness.
Shen W; Xie J; Zhao S; Du R; Luo X; He H; Jiang S; Hao N; Chen C; Guo C; Liu Y; Chen Y; Sun P; Yang S; Luo N; Xiang R; Luo Y
Cancer Lett; 2018 May; 422():29-43. PubMed ID: 29477378
[TBL] [Abstract][Full Text] [Related]
4. HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
La Noce M; Paino F; Mele L; Papaccio G; Regad T; Lombardi A; Papaccio F; Desiderio V; Tirino V
J Exp Clin Cancer Res; 2018 Dec; 37(1):296. PubMed ID: 30509303
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.
Meng F; Sun G; Zhong M; Yu Y; Brewer MA
Int J Oncol; 2013 Aug; 43(2):495-502. PubMed ID: 23709006
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer.
Song M; Ping Y; Zhang K; Yang L; Li F; Zhang C; Cheng S; Yue D; Maimela NR; Qu J; Liu S; Sun T; Li Z; Xia J; Zhang B; Wang L; Zhang Y
Cancer Res; 2019 Jul; 79(14):3737-3748. PubMed ID: 31085700
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics in cancer stem cells.
Toh TB; Lim JJ; Chow EK
Mol Cancer; 2017 Feb; 16(1):29. PubMed ID: 28148257
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
[TBL] [Abstract][Full Text] [Related]
9. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane suppresses in vitro and in vivo lung tumorigenesis through downregulation of HDAC activity.
Jiang LL; Zhou SJ; Zhang XM; Chen HQ; Liu W
Biomed Pharmacother; 2016 Mar; 78():74-80. PubMed ID: 26898427
[TBL] [Abstract][Full Text] [Related]
12. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
Liau BB; Sievers C; Donohue LK; Gillespie SM; Flavahan WA; Miller TE; Venteicher AS; Hebert CH; Carey CD; Rodig SJ; Shareef SJ; Najm FJ; van Galen P; Wakimoto H; Cahill DP; Rich JN; Aster JC; Suvà ML; Patel AP; Bernstein BE
Cell Stem Cell; 2017 Feb; 20(2):233-246.e7. PubMed ID: 27989769
[TBL] [Abstract][Full Text] [Related]
13. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
14. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
15. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Marampon F; Leoni F; Mancini A; Pietrantoni I; Codenotti S; Ferella L; Megiorni F; Porro G; Galbiati E; Pozzi P; Mascagni P; Budillon A; Maggio R; Tombolini V; Fanzani A; Gravina GL; Festuccia C
J Cancer Res Clin Oncol; 2019 Feb; 145(2):393-409. PubMed ID: 30474756
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of KLF4 by methylseleninic acid in human esophageal squamous cell carcinoma cells: Modification of histone H3 acetylation through HAT/HDAC interplay.
Hu C; Liu M; Zhang W; Xu Q; Ma K; Chen L; Wang Z; He S; Zhu H; Xu N
Mol Carcinog; 2015 Oct; 54(10):1051-9. PubMed ID: 24789055
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1.
Zhou TJ; Zhang SL; He CY; Zhuang QY; Han PY; Jiang SW; Yao H; Huang YJ; Ling WH; Lin YC; Lin ZN
Theranostics; 2017; 7(5):1389-1406. PubMed ID: 28435473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
